Presenter: D. J. Rizzo Affiliation: NCI, Bethesda, MD
Increased survival has been seen in pateints with Hodgkin?s disease and Non-Hodgkin?s lymphoma who underwent autotransplantation, with a 40-50% long-term disease-free-survival rate.
However, previous reports indicate that pts receiving autotransplants for lymphoma have an increased risk of MDS/Leukemia.
The separate contributions of pre-tranplant and tranplant-related therapy to this risk are not well chararcterized.
Materials and Methods:
Case-control study of 56 pts with MDS/leukemia from 955 pts receiving autotransplants for HD and 1784 for NHL, 1989- 1995 at 12 institutes in North America with follow up through Dec. 31, 1996.
Three age-, sex- and latency-matched controls were randomly selected for each case.
Medical records reviewed to determine all pre- and post- transplant therapy and related procedures.
In multivariate analyses, pre-transplant chemotherapy is the largest contributor for risk of developing MDS/leukemia. With 4- and 10- fold increased risks in pts given mechlorethamine (MOPP-like regimen) and chlorambucil (p <0.05), compared to those given only cyclophosphamide- based treatment (2 fold).
Risk increased with increasing dose of mechlorethamine > 50 mg/m2 (Relative risk 4.8) and increasing duration of chlorambucil ( > 10mos, RR 16.8)
For total body irradiation (TBI), no substantial increased risk observed for dose < 12Gy (RR1.4). However, for doses of 13.2 Gy, there was statistically significant 4-5 fold (p=0.02) increased risk.
Peripheral blood vs bone marrow stem cell transplantation had statistcally significant 2 fold increased risk (p<0.05) in univariate but not in multivariate analyses.
No assoication between graft purging or use of mobilization chemotherapy/growth factors and MDS/leukemia.
The types and intesity of conventional pre- transplant chemotherapy has the strongest impact on developing MDS/leukemia after autotransplantation.
Although some transplant-related factors (grafting, TBI, high dose chemotherapy, purging, priming) may also play a role these findings required confirmation on other patient populations.
Additional information reported by presenter that 33/37 patients who had post-transplant cytogenetic study showed positivity for cytogenetic evidence for MDS. Further reviews of patients?s pre-transplant cytogenetic status of MDS is underway.
Avoidance of using MOPP or MOPP-like regimen should be undertaken in order to decrease incidence of secondary MDS/leukemia as increasing numbers of patients undergoing bone marrow or peripheral stem cell transplantation.
Jan 17, 2013 - For patients treated for Hodgkin's lymphoma, cumulative doses of alkylating agent is associated with the risk of therapy-related acute myeloid leukemia/myelodysplastic syndrome, according to a study published online Jan. 7 in the Journal of Clinical Oncology.